Shire plc ("the Company") and its subsidiaries (collectively referred to as the "Group" or "Shire") develop and market products for specialty physicians. The Group focuses on four therapeutic areas: ADHD, gastro-intestinal ("GI"), human genetic therapies ("HGT") and renal diseases.
The Company is a public limited company incorporated under the Companies Act, 1985 and domiciled in the United Kingdom. The address of its registered office is Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP, United Kingdom.
The Company has its primary listing on the London Stock Exchange and its secondary listing on the NASDAQ National Market in the United States of America.
These accounts are presented in US Dollars as this is the currency of the primary economic environment in which the Group operates.
2. Accounting Presentation and Policies
These unaudited interim financial statements for the six months to June 30, 2007 have been prepared in accordance with International Accounting Standards and International Financial Reporting Standards ("IFRS") as adopted by the EU. Other than noted below in respect of convertible bonds, the accounting policies adopted are consistent with those followed in the preparation of the Group's Annual Report for the year ended December 31, 2006. The balance sheet at December 31, 2006 has been derived from the full Group accounts published in the Annual Report for the year ended December 31, 2006, which have been delivered to the Registrar of Companies and on which the report of the independent auditors was unqualified and did not contain a statement under either section 237(2) or 237(3) of the Companies Act 1985. The financial information for the year ended December 31, 2006 included in this report does not constitute statutory accounts as defined in section 240 of the Companies Act 1985.
On issue the Company bifurcates convertible bonds into their debt and
|SOURCE Shire plc|
Copyright©2007 PR Newswire.
All rights reserved